Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease
Research Report
Washington D.C. Pharma Co. Receives FDA Acceptance
Research Report
Biotech's Target Price 183.757% Higher Than Current
Research Report
AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery
Biopharma Shares Multiple 2025 Catalysts
Research Report
Tech Innovator Achieves Breakthrough Multi-Market Success
Advanced AI Solutions Deliver Hope for CNS Cancer Treatment
AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research.Pharma Innovator Reveals Groundbreaking Diabetes Treatment
Research Report
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share. Biotech Advances Breakthrough Cancer Treatment Results
Research Report
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note. Should You Double Down on This Story Stock?
Contributed Opinion
Chris Temple of The National Investor explains why he believes you might want to double down on BioLargo Inc. (BLGO:OTCQX). AI Company Unlocks Breakthrough Medical Diagnostics Platform
One company being listed on Cboe Canada starting January 8 is using AI and smartphones to help patients get quick and accurate diagnosis of their sore throats, helping to battle microbial resistance that threatens the effectiveness of antibiotics worldwide.Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence.Pharma Innovator Unlocks Multi-Disease Treatment Potential
Research Report
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating. Drug Innovator Launches Pivotal Cancer Trial Breakthrough
Research Report
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note. Miami Biopharma Sells Part of Business and Begins New Clinical Trial
Research Report
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating. 
Streetwise Key Charts
